Evidence map›Paper›PMID 39519121›Full record

ArticleInternational journal of molecular sciences2024

The Therapeutic Potential of Exosomes vs. Matrix-Bound Nanovesicles from Human Umbilical Cord Mesenchymal Stromal Cells in Osteoarthritis Treatment.

Timofey O Klyucherev, Maria A Peshkova, Daria P Revokatova, Natalia B Serejnikova, Nafisa M Fayzullina, Alexey L Fayzullin, Boris P Ershov, Yana I Khristidis, Irina I Vlasova, Nastasia V Kosheleva and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Timofey O KlyucherevInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0003-3751-9589
Maria A PeshkovaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0001-9429-6997
Daria P RevokatovaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-7539-2403
Natalia B SerejnikovaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-4097-1552
Nafisa M FayzullinaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Alexey L FayzullinInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0003-4137-8993
Boris P ErshovInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Yana I KhristidisInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Irina I VlasovaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Nastasia V KoshelevaInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Andrey A SvistunovSechenov First Moscow State Medical University, 119991 Moscow, Russia.
Peter S TimashevInstitute for Regenerative Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.

Funding

the Ministry of Science and Higher Education of the Russian Federation 075-15-2024-640 (Sechenov University)
6 · The paper itself

Abstract

Osteoarthritis (OA) is a degenerative joint disease with limited therapeutic options, where inflammation plays a critical role in disease progression. Extracellular vesicles (EV) derived from mesenchymal stromal cells (MSC) have shown potential as a therapeutic approach for OA by modulating inflammation and alleviating degenerative processes in the joint. This study evaluated the therapeutic effects for the treatment of OA of two types of EV-exosomes and matrix-bound nanovesicles (MBV)-both derived from the human umbilical cord MSC (UC-MSC) via differential ultracentrifugation. Different phenotypes of human monocyte-derived macrophages (MDM) were used to study the anti-inflammatory properties of EV in vitro, and the medial meniscectomy-induced rat model of knee osteoarthritis (MMx) was used in vivo. The study found that both EV reduced pro-inflammatory cytokines IL-6 and TNF-α in MDM. However, exosomes showed superior results, preserving the extracellular matrix (ECM) of hyaline cartilage, and reducing synovitis more effectively than MBVs. Additionally, exosomes downregulated inflammatory markers (TNF-α, iNOS) and increased Arg-1 expression in macrophages and synovial fibroblasts, indicating a stronger anti-inflammatory effect. These results suggest UC-MSC exosomes as a promising therapeutic option for OA, with the potential for modulating inflammation and promoting joint tissue regeneration.

Indexed as

ExosomesMesenchymal Stem CellsOsteoarthritisUmbilical CordAnimalsDisease Models, AnimalExtracellular MatrixExtracellular VesiclesHumansMacrophagesMaleRatsexosomesmatrix-bound nanovesiclesmesenchymal stromal cellsmonocyte-derived macrophagesosteoarthritis

Identifiers

PMID39519121
PMCPMC11545893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.